# InflaRx N.V. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/InflaRx N.V.). ## Overview InflaRx N.V. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies that target the complement system, particularly the C5a/C5aR pathway. The group operates through wholly owned subsidiaries in Germany and the United States, with its principal place of business in Jena, Germany. ## Products & services • Anti-C5a and anti-C5aR drug discovery • Izicopan oral small-molecule program • Vilobelimab intravenous monoclonal antibody • Clinical development for inflammatory diseases • Commercialization of complement-targeted therapeutics - **Complement-targeted therapeutics** (50%) — Drug programs designed to inhibit C5a or the C5a receptor in inflammatory disease. - **Lead clinical candidate: izicopan** (25%) — Orally administered small-molecule program under clinical development. - **Lead biologic: vilobelimab** (15%) — Intravenous anti-C5a monoclonal antibody and related development activity. - **Preclinical and translational research** (10%) — Research efforts that support new anti-inflammatory pipeline assets. - Anti-C5a and anti-C5aR drug discovery - Izicopan oral small-molecule program - Vilobelimab intravenous monoclonal antibody - Clinical development for inflammatory diseases - Commercialization of complement-targeted therapeutics ## Customers InflaRx does not sell to traditional end-market customers in the way a commercial pharmaceutical company does; its primary counterparties are clinical investigators, trial sites, and eventually healthcare providers and payers if a product is approved. In the development stage, value is created through progression of drug candidates for inflammatory diseases such as hidradenitis suppurativa, AAV, and renal diseases. - **Clinical trial ecosystem** (primary) — Trial sites, investigators, and study vendors that execute izicopan and vilobelimab development programs. - **Specialty physicians** (primary) — Specialists in immunology, nephrology, and dermatology who would prescribe if products are approved. - **Healthcare payers** (secondary) — Public and private payers that determine reimbursement for approved specialty therapies. - **Research collaborators** (secondary) — Academic and industry partners that may support discovery, biomarker work, or clinical research. - Clinical investigators and trial sites running development studies - Hospitals and specialists treating inflammatory disease patients - Payers and reimbursement systems after potential approval - Research partners supporting translational and clinical work - Patients with complement-mediated inflammatory diseases ## Geography InflaRx is headquartered in Jena, Germany, and also maintains offices in Munich and Ann Arbor, Michigan through wholly owned subsidiaries. Its business is organized across Germany and the United States, reflecting a transatlantic development footprint rather than a broad commercial sales network. - **Germany** (50%) — Principal operating base and headquarters - **United States** (50%) — Wholly owned U.S. subsidiary and office - Head office and principal place of business in Jena, Germany - Additional offices in Munich, Germany - U.S. subsidiary and office in Ann Arbor, Michigan - Development footprint spans Europe and the United States - No country-level revenue disclosure was provided ## Strategy InflaRx’s strategy is centered on building a pipeline around its proprietary anti-C5a and anti-C5aR platform and advancing lead assets through clinical development. The company aims to demonstrate disease-modifying activity in inflammatory disorders where complement biology is relevant and where differentiated mechanisms may support future commercialization. - **Progress izicopan clinical development** (short-term) — Clinical success is central to validating the platform and creating future product value. - **Advance vilobelimab in inflammatory indications** (medium-term) — A differentiated biologic asset can broaden the pipeline and support partnering or commercialization options. - **Leverage complement-pathway expertise** (long-term) — A focused scientific platform can improve target selection and pipeline efficiency. - Advance izicopan through later-stage clinical development - Develop vilobelimab for complement-mediated inflammatory disease - Use proprietary anti-C5a/C5aR biology as a platform - Target high-unmet-need specialty indications - Translate clinical signals into future commercialization ## Risks As a clinical-stage biopharmaceutical company, InflaRx depends on successful trial execution, regulatory outcomes, and scientific validation of its complement-focused mechanism. It also faces financing, manufacturing, and commercialization risks typical of drug developers, where delays or negative data can materially affect future prospects. - **Clinical development failure** [critical] — Lead assets depend on positive data from Phase 1/2 studies and later-stage trials. - **Regulatory approval risk** [high] — Novel anti-inflammatory mechanisms must satisfy safety and efficacy standards. - **Future funding needs** [high] — Clinical-stage biopharma typically consumes cash before product revenue exists. - **Competitive scientific landscape** [medium] — Other immunology and inflammation approaches may capture trial sites, partners, or patients. - Clinical trial failure could eliminate value in lead programs - Regulatory risk remains high for novel inflammatory therapies - Funding needs can constrain development timelines - Manufacturing and supply complexity affect biologics and small molecules - Competitive pressure from other immunology platforms ## Accounting The most important accounting judgments for InflaRx relate to R&D expense recognition, clinical trial accruals, and the valuation of share-based compensation and any financial instruments. Because the company is development-stage, period-to-period results can be heavily affected by estimates for outsourced trial costs, foreign exchange, and the timing of milestone or collaboration-related items if present. - **R&D accruals and clinical trial estimates** — Can shift reported research expense between periods - **Share-based compensation** — Affects operating expenses and net loss - **Foreign currency translation** — Can create volatility in reported results and cash balances - **Intangible asset impairment** — Could lead to write-downs if programs disappoint - R&D expense accruals depend on estimated clinical trial activity - Share-based compensation can materially affect operating loss - Foreign exchange matters because reporting is in euros - Clinical development costs may be uneven across quarters - Asset impairment risk is relevant for capitalized intangibles --- *Last updated: 2026-09-28T12:04:04.989634+00:00*